KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies worldwide. With a focus on quality, speed, and client collaboration, KBI offers a broad range of services including cell line development, process development (upstream and downstream), analytical development and cGMP testing, and cGMP manufacturing of mammalian and microbial-based drug substances and drug products. Their expertise spans various modalities, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies, helping clients advance their novel biological candidates from early discovery to commercialization.
The Durham headquarters serves as the central node for KBI's global operations, housing corporate leadership, strategic planning, core research and development activities, process development labs, and cGMP manufacturing capabilities.
The Durham facility boasts state-of-the-art laboratories for cell line development, process and analytical development, and extensive cGMP manufacturing suites for both microbial and mammalian production. It's designed to support end-to-end biopharmaceutical development.
The work culture at KBI Biopharma's headquarters is characterized by a strong emphasis on scientific rigor, innovation, collaboration, and a client-centric approach. Employees often work in cross-functional teams on cutting-edge projects, fostering a dynamic and intellectually stimulating environment.
Its strategic location in Research Triangle Park provides KBI with access to a highly skilled talent pool, leading academic institutions, and a vibrant ecosystem of biotech companies and collaborators, facilitating innovation and growth.
KBI Biopharma supports its global client base through a strategically located network of facilities across North America (USA: North Carolina, Colorado, Texas) and Europe (Switzerland, Belgium). These sites offer a comprehensive suite of services including cell line development (mammalian and microbial), upstream and downstream process development, advanced analytical testing and characterization, formulation development, and cGMP manufacturing of drug substances and drug products. This global footprint allows KBI to cater to regional needs while maintaining consistent quality and expertise across all operations.
5927 S Miami Blvd
Durham
North Carolina
USA
Address: 2500 Central Avenue & 2465 Central Avenue, Boulder, CO 80301
Serves as a key microbial center of excellence within North America, supporting clients with microbial-derived biotherapeutics.
Address: 21 Waterway Avenue, Suite 550, The Woodlands, TX 77380
Provides critical cell line development and analytical services, supporting the initial phases of mammalian biotherapeutic programs in North America.
Address: Chemin des Aulx 14, 1228 Plan-les-Ouates, Geneva, Switzerland
Expands KBI's global reach, providing comprehensive CDMO services to the European biopharmaceutical market and facilitating international collaborations.
Address: Technologielaan 11, 3001 Leuven, Belgium
Strengthens KBI's analytical capabilities in Europe, offering specialized characterization services crucial for biopharmaceutical development and regulatory submissions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, KBI Biopharma' leadership includes:
KBI Biopharma has been backed by several prominent investors over the years, including:
KBI Biopharma has recently made strategic appointments to its executive team to bolster its commercial operations and overall leadership.
Discover the tools KBI Biopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
KBI Biopharma commonly uses the email format combining the first initial and last name. Understanding this pattern can be useful for professional communication.
[first_initial][last]@kbibiopharma.com
Format
jdoe@kbibiopharma.com
Example
85%
Success rate
KBI Biopharma Press Release • April 16, 2024
KBI Biopharma announced the appointment of Sigma Mostafa, PhD, as its new Chief Commercial Officer. Dr. Mostafa will lead KBI's global commercial strategy and operations, bringing extensive experience in the biopharmaceutical CDMO sector....more
KBI Biopharma Press Release • February 13, 2024
KBI Biopharma and ARGX entered into a strategic collaboration to leverage KBI's advanced manufacturing platform and expertise to accelerate the development and supply of ARGX's innovative antibody-based therapies....more
KBI Biopharma Press Release • October 11, 2023
KBI Biopharma and Nuclera formed a strategic collaboration to integrate Nuclera's eProtein™ drug discovery platform with KBI's downstream services, aiming to streamline biologics drug discovery workflows....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including KBI Biopharma, are just a search away.